- Home
- AEE vs ILMN Comparison
AEE vs ILMN Comparison
Compare AEE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- ILMN
- Stock Information
- Founded
- AEE 1901
- ILMN 1998
- Country
- AEE United States
- ILMN United States
- Employees
- AEE N/A
- ILMN N/A
- Industry
- AEE Power Generation
- ILMN Medical Specialities
- Sector
- AEE Utilities
- ILMN Health Care
- Exchange
- AEE Nasdaq
- ILMN Nasdaq
- Market Cap
- AEE 26.0B
- ILMN 13.1B
- IPO Year
- AEE N/A
- ILMN 2000
- Fundamental
- Price
- AEE $96.53
- ILMN $99.25
- Analyst Decision
- AEE Buy
- ILMN Buy
- Analyst Count
- AEE 11
- ILMN 17
- Target Price
- AEE $100.91
- ILMN $124.35
- AVG Volume (30 Days)
- AEE 1.7M
- ILMN 2.4M
- Earning Date
- AEE 07-31-2025
- ILMN 07-31-2025
- Dividend Yield
- AEE 2.95%
- ILMN N/A
- EPS Growth
- AEE 3.54
- ILMN N/A
- EPS
- AEE 4.51
- ILMN N/A
- Revenue
- AEE $7,596,000,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- AEE $13.04
- ILMN N/A
- Revenue Next Year
- AEE $5.42
- ILMN $3.15
- P/E Ratio
- AEE $21.36
- ILMN N/A
- Revenue Growth
- AEE 9.04
- ILMN N/A
- 52 Week Low
- AEE $71.87
- ILMN $68.70
- 52 Week High
- AEE $104.10
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- AEE 51.36
- ILMN 65.51
- Support Level
- AEE $94.20
- ILMN $95.09
- Resistance Level
- AEE $96.46
- ILMN $101.28
- Average True Range (ATR)
- AEE 1.27
- ILMN 3.28
- MACD
- AEE 0.11
- ILMN 0.10
- Stochastic Oscillator
- AEE 74.71
- ILMN 78.82
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.